Request Demo

Last update 24 May 2025

Cefixime

Last update 24 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(−)-cefixim, Cefixime (INN), Cefixime anhydrous

+ [14]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersMouth and Tooth Diseases+ [3]

Active Indication

Bronchitis, ChronicGonorrheaPharyngitis+ [14]

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Lupin Ltd

Choseido Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan General Pharmaceutical Factory

+ [1]

Inactive Organization

Lederle Laboratories

License Organization

Otsuka Chemical Co., Ltd.

Astellas Pharma, Inc.

Otsuka Holdings Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (30 Jun 1987),

Acute BronchitisCholecystitisCystitis+ [7]

Regulation-

Structure/Sequence

Molecular FormulaC16H21N5O10S2

InChIKeyIPYWNMVPZOAFOQ-NABDTECSSA-N

CAS Registry125110-14-7

123

Clinical Trials associated with Cefixime

NCT06406114

/ RecruitingPhase 2IIT

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date29 Apr 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

CTR20250796

/ Active, not recruitingNot Applicable

中国健康受试者空腹和餐后口服头孢克肟干混悬剂单中心、开放、随机、单剂量、两周期、两序列、双交叉设计的生物等效性试验

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, double-crossover bioequivalence study of cefixime dry suspension in Chinese healthy volunteers after fasting and feeding

主要研究目的研究空腹和餐后状态下单次口服受试制剂头孢克肟干混悬剂（规格：0.8g（100mg/5ml），上海金城素智药业有限公司提供）与参比制剂头孢克肟干混悬剂（规格：100mg/5ml，持证商：AMDIPHARM LIMITED），在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后状态下，单次口服头孢克肟干混悬剂受试制剂和参比制剂后的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of a single oral dose of the test preparation cefixime dry suspension (specification: 0.8g (100mg/5ml), provided by Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd.) and the reference preparation cefixime dry suspension (specification: 100mg/5ml, licensee: AMDIPHARM LIMITED) in healthy adult subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations when taken orally on a fasting and fed basis. Secondary study objectives To evaluate the safety of a single oral dose of the test preparation and reference preparation of cefixime dry suspension in healthy Chinese subjects under fasting and fed conditions.

Start Date11 Apr 2025

Sponsor / Collaborator

Shanghai Jincheng Pharmaceutical Co. Ltd.

TCTR20250410003

/ Active, not recruitingNot ApplicableIIT

Efficacy and Safety of direct drug provocation test in children with benign cutaneous immediate hypersensitivity reaction to Beta-lactams

Start Date09 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Cefixime

100 Translational Medicine associated with Cefixime

100 Patents (Medical) associated with Cefixime

9,924

Literatures (Medical) associated with Cefixime

01 Dec 2025·Current HIV/AIDS Reports

Expanding Horizons in Syphilis Treatment: Challenges, Advances, and Opportunities for Alternative Antibiotics

Review

Author: Villarreal, Diana D ; Babalola, Chibuzor M

Abstract:

Purpose of Review:

This review examines the growing need for alternative technologies to address the resurgence of syphilis, particularly its congenital and late-stage manifestations. It explores current treatment paradigms, highlights the limitations of penicillin, and evaluates emerging evidence on new therapies and diagnostics to inform future strategies.

Recent Findings:

Recent breakthroughs in Treponema pallidum culture techniques have enabled antibiotic susceptibility testing, expanding knowledge on both established and emerging treatment options. Alternatives like ceftriaxone, doxycycline, cefixime, and dalbavancin show promise, with other candidates in trials, though evidence is limited beyond early-stage syphilis. Shortened penicillin regimens also challenge historical assumptions about treatment duration. Advanced molecular diagnostics may complement currently limited serologic monitoring to improve evaluations in healthcare and research.

Summary:

While penicillin remains effective, its limitations necessitate alternatives. Emerging antibiotics and improved diagnostics offer opportunities to simplify treatment and enhance care. Future robust trials should validate new treatments, refine dosing strategies, and integrate innovative diagnostics, particularly including underserved and vulnerable populations.

01 Sep 2025·WATER RESEARCH

Temporal dynamics of class 1 and class 3 integron pools in treated wastewater

Article

Author: Henriques, Isabel ; Rodrigues, Elsa T ; Tacão, Marta ; Tavares, Rafael D S

Wastewater is a hotspot for the spread and evolution of antimicrobial resistance (AMR), with integrons playing a key role in the dissemination of AMR. However, there is limited information available regarding the integron pool of wastewater environments. The present study aims to characterize the integron pool in outflow secondary-treated municipal wastewater samples collected weekly over the course of a year (n = 52 samples) and to identify the risks associated with the carriage of clinically relevant antimicrobial resistance gene cassettes (ARGCs). Integron arrays were amplified with the primer combinations intI-R/3'CS and intI3F/class3R. PacBio long-read sequencing was performed on 12 monthly pooled samples per primer pair. The analysis yielded 283,579 integron reads, capturing an estimated 10%-20% of the total integron pool, with the most abundant arrays successfully recovered. Most identified GCs had no known function (33.3% to 74.5% depending on integron class). Regarding GCs with known function, AMR was the most prevalent function in class 1 integrons. Class 3 integrons primarily encoded defence mechanisms and amino acid transport and metabolism, while cassettes associated with replication, recombination and repair were abundant in integrons of unknown class. The prevalence of ARGCs for class 1, 3 and integrons of unknown class was 61.7%, 19.2% and 9.6%, respectively. Most ARGCs (from the 146 identified) encoded resistance to aminoglycosides and beta-lactams, the most abundant being aadA10, aac(6')-IIc and bla_GES-5. Most beta-lactamase-encoding GCs (BLGCs) identified encoded enzymes with carbapenemase and/or extended-spectrum activity, with class 1 and class 3 integrons being relevant reservoirs of BLGCs. GCs encoding proteins involved in oxidative stress repair, as well as in other functions, were also identified and might promote co-selection of ARGCs. Large variation of the integron arrays and the GC pool was observed between seasons and pooled monthly samples, with resistance genotypes such as macrolide and phenicol resistance differentially abundant across seasons. Overall, these findings show that secondary-treated wastewater is a reservoir of highly diverse class 1 and class 3 resistance integrons, some encoding critically relevant resistance mechanisms (e.g., carbapenemases).

01 Aug 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Enhanced antibiotic removal via magnetic Ni@ZIF-8 composite nanotubes: Synergistic adsorption, facile recovery and adsorption mechanism

Author: Li, Xiangzi ; Wang, Meifang ; Zhao, Ruirui ; Cheng, Xiaomei ; Chen, Zhiming ; Fu, Mengxian ; Zhang, Changfang ; Zhang, Chuanqi

The integration of metal-organic framework (MOF) materials with magnetic cores not only serves as an effective adsorbent but also facilitates the recovery post-adsorption.In this study, we synthesized Ni@ZIF-8 composite nanotubes by introducing ZIF-8 onto the surface of Ni nanotubes, which were used as adsorbents for antibiotic removal.The Ni@ZIF-8 composite nanotubes exhibited high-efficiency and recyclable antibiotic adsorption, with the maximum adsorption capacities for tetracycline (TC) and cefixime (CFX) reaching 770.2 and 428.2 mg·g^-1, resp.The Ni nanotubes, acting as magnetic cores, facilitated magnetic recovery after adsorption.Furthermore, the introduction of ZIF-8 not only increased the surface roughness of the composite but also incorporated a significant number of functional groups.The pseudo-second-order model, Langmuir model and intra-particle diffusion models provided better fits to the isotherm and kinetic data of the two antibiotics.D. functional theory (DFT) calculations results indicate that the π-π interactions dominate the adsorption process of both TC and CFX onto ZIF-8.And the electrostatic potential (ESP) calculations and interaction anal. indicate that the Ni atom enhances the adsorption behavior through π-π interactions between the benzene ring or carbonyl group of the two antibiotics and the imidazole of ZIF-8.This research offers a novel approach for the removal of antibiotics from contaminated water and environmental remediation using magnetic core-MOF composite materials.

News (Medical) associated with Cefixime

29 Nov 2024

·pharma.economictimes.indiatimes.com

CDSCO monthly review finds 56 drugs as substandard, flags 3 as spurious

New Delhi: As part of its monthly review undertaken to check and enforce the quality standards in the consumer drug market, the Central Drugs Standard Control Organization ( CDSCO ) has identified 56 drug samples as ‘Not of Standard Quality’ (NSQ) and 3 as ‘spurious.’ The drugs and formulations which have been classified as spurious picked by Bihar Drugs Control Authority include Pantoprazole Gastro-resistant and Domeperiodone Prolong Released Capsules IP ( PAN-D); Cefixime Tablets IP (TAXIM-O 200); and Rosuvastatin Tablets IP (Rosuvas 10). As per the CDSCO notification, each of these drugs were manufactured in 2023 and the central drugs regulator is still investigating the manufacturer of the above-mentioned spurious drugs . The list of drugs and formulations which have been identified as NSQ includes Trypsin & Chymotrypsin Tablets manufactured by Cachet Pharmaceuticals Private Limited; Diclofenac Sodium, Paracetamol & Chlorzoxazone Tablets by MODERN LABORATORIES; Liposomal Amphotericinn B Injection 50mg by UNITED BIOTECH (P) LIMITED; Ornidazole & Ofloxacin Tablets IP by Hindustan Antibiotics Ltd; Amlodipine and Perindopril Tablets by Intas Pharmaceuticals Ltd.; Natamycin Ophthalmic Suspension by Primus Pharmaceuticals, among 50 others. All samples notified under the NSQ list for the month of October (released in November) were manufactured between 2022 and 2024, and CDSCO has identified the manufacturers of each of the listed products. Meanwhile, during the same period the State Drugs Testing Laboratories across the country have identified 34 Drugs Samples as Not of Standard Quality (NSQ). According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; or if it is an imitation of, or a substitute for, another drug; or resembles another drug in a manner likely to deceive or bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas those drugs that fail to meet the quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

NDADrug Approval

24 Nov 2024

·pharma.economictimes.indiatimes.com

Telangana: DCA raids quack's clinic in Khammam, seizes illegal stock of drugs

Hyderabad: The Drugs Control Administration (DCA) of Telangana has raided a quack's clinic in Kakarvai village at Telangana's Khammam, and seized a stock of drugs being sold without a valid drug licence, officials said on Saturday. According to DCA officials, on credible information, its officials raided the premises of a quack Parala Anjaiah who was practising medicine without proper qualification at his clinic on Friday. During the raid, DCA officials detected 55 varieties of medicines, including antibiotics, steroids, analgesics etc., found stocked at the premises without a drug licence. DCA officials seized the stock, worth a total of Rs. 84,760 during the raid. DCA officials detected several higher generation 'antibiotics' viz. Cefixime, Cefuroxime etc. at the clinic during the raids. Indiscriminate sale of antibiotics, by unqualified persons may have disastrous consequences on the health of the public, including the emergence of 'Antimicrobial Resistance'. Officials found 'steroids' viz. Dexamethasone, Prednisolone etc. at the clinic of quack. Misusing steroids can have serious health consequences, including immune system suppression, hormonal imbalances, muscle and bone weakness, cardiovascular problems, and psychological effects. The indiscriminate use of steroids poses significant risks to public health. Further investigation will be carried out, and action will be taken as per the law against all the offenders. In addition, DCA officials also detected certain medicines circulating in the market with misleading claims on their labels, stating that they treat obesity, convulsions, kidney Stones, and high blood pressure. Such claims are in contravention of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. The DCA has assured that further investigation will be carried out, and action will be taken against those responsible. (ANI)

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

100 Deals associated with Cefixime

External Link

KEGG	Wiki	ATC	Drug Bank
D00258	Cefixime	J01DD08	DB00671

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis, Chronic	United States	Lupin Ltd	01 Jun 2012
Gonorrhea	United States	Lupin Ltd	01 Jun 2012
Pharyngitis	United States	Lupin Ltd	01 Jun 2012
Tonsillitis	United States	Lupin Ltd	01 Jun 2012
Urinary Tract Infections	United States	Lupin Ltd	01 Jun 2012
Bacterial Infections	China	Guangzhou Baiyunshan General Pharmaceutical Factory	01 Jan 1993
Infectious Diseases	United States	Lederle Laboratories	28 Apr 1989
Acute Bronchitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Cholecystitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Cystitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Otitis Media	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Pneumonia	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Pyelonephritis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Scarlet Fever	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Secondary infection	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Sinusitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987
Urethritis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1987

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03969758 (clinicaltrials.gov PRS ID: NCT03969758, 31/05/2019, Pubmed)	Phase 3	Liver Abscess	140	Ciprofloxacin	svosnnqlqo(lcclprzcvd) = sewxpxrfya lmkvexgrrv (mselbetpyt ) View more	Positive	20 May 2024
				Cefixime	svosnnqlqo(lcclprzcvd) = qnpgdwkwod lmkvexgrrv (mselbetpyt ) View more
NCT03660488 (CTgov)	Phase 2	Syphilis	58	Benzathine Penicillin G (Benzathine Penicillin G)	kjwpwzxxrb = yprafeffko cwnclplgge (namymucupk, sgklkbroea - gzmupgpdwy) View more	-	26 Jul 2022
				Cefixime 400 milligram Oral Capsule [Suprax] (Cefixime Group)	kjwpwzxxrb = nrfyzglmqz cwnclplgge (namymucupk, mfpcyivlya - plxynqibep) View more
NCT05216744 (Pubmed \| BMC Infect Dis) Manual	Phase 2	Gonorrhea \| Chlamydia trachomatis infection	125	Ceftriaxone + Doxycycline	pdxiaoxppt(lcrexrztot) = hwegkkdeex dhhlohexoi (hvpzizoiwu, 88.8 - 99.1)	Positive	09 Jul 2022
				Cefixime + Doxycycline	pdxiaoxppt(lcrexrztot) = bpkmcnreyq dhhlohexoi (hvpzizoiwu, 87.1 - 98.4)
IAS2022	Not Applicable	-	-	Cefixime 400 mg single dose	rqzvundmlv(giqcipuyhd) = ckbcuzawwy mthhsepjjn (hmqhrhvzsq, 76.9 - 95.0) View more	-	01 Jan 2022
				Cefixime 800 mg single dose	rqzvundmlv(giqcipuyhd) = irxoeifgyf mthhsepjjn (hmqhrhvzsq, 66.3 - 96.2) View more
NCT01595529 (SCOUT, CTgov)	Phase 2	Urinary Tract Infections	717	Cephalexin+Trimethoprim-sulfamethoxazole (TMP-SMX)+Sulfamethoxazole+Trimethoprim+Cefdinir+Cefixime (Standard Course Treatment)	luimsddnpr = zqjinckelf redklunbxq (uypxtwjrux, dmmvdgizic - cxxkuivpjr) View more	-	13 Jul 2020
				placebo (Short Course Treatment)	luimsddnpr = fqugmymuyv redklunbxq (uypxtwjrux, hkxdnjhigd - nyjehlpabz) View more
NCT03408392 (CTgov)	Phase 1	Bacterial Infections	28	SKF101804 (SKF101804 Cefixime)	jyxowoxfst(tzdokgdsbi) = upxfoovfcg onoaciubin (ijquoiqjsf, 32.9) View more	-	22 Mar 2019
				Cefixime (Cefixime Reference Formulation)	jyxowoxfst(tzdokgdsbi) = iuvggtzevl onoaciubin (ijquoiqjsf, 34.3) View more
ERS2011	Not Applicable	Community Acquired Pneumonia	63	Azithromycin (500 mg) intravenously (i.v.) once daily followed by 250 mg orally twice daily	cokydmimpf(mwupvhignf) = ifkryecdra wrwqjssgxl (sfvuhjkpui ) View more	Positive	01 Sep 2011
				Ceftriaxone (2 g) by i.v. infusion twice daily followed by Cefixime (400 mg) twice daily	cokydmimpf(mwupvhignf) = jmcsxsisxn wrwqjssgxl (sfvuhjkpui ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cefixime

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation